Last reviewed · How we verify
NCT05605678
Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)
trial testing No Intervention in Hemophilia a in 108 participants. Terminated before completion.
29 November 2024
Quick facts
| Lead sponsor | ApcinteX Ltd |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 108 |
| Start date | 9 December 2022 |
| Primary completion | 29 November 2024 |
| Estimated completion | 29 November 2024 |
| Sites | 45 locations across France, Italy, South Africa, Turkey (Türkiye), Taiwan, United Kingdom, Germany, Poland |
Drugs / interventions tested
- No Intervention
Conditions studied
- Hemophilia a — all drugs for Hemophilia a →
- Hemophilia B — all drugs for Hemophilia B →
Sponsor
ApcinteX Ltd — full company profile →
Who can join
Adults 12 to 65, male only, with Hemophilia a or Hemophilia B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to obtain prospective baseline documentation of annualized bleeding rates (ABRs) and treatment under standard-of-care (SOC) therapy among participants with hemophilia A or B. Participants in the study may be eligible to enroll in future planned interventional studies to be conducted by Sponsor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05605678
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention
Trials testing the same drug.
- NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
- NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
- NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
- NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
- NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
Other recruiting trials for Hemophilia a
Currently open trials in the same condition.
- NCT06565481 — Measurement Properties in People with Hemophilia · NA · recruiting
- NCT06702579 — Home Monitoring in Hemophilia a · recruiting
Other ApcinteX Ltd trials
Trials by the same sponsor.
- NCT06568302 — The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Tr · Phase 3 · terminated
- NCT05789537 — A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors · Phase 2 · terminated
- NCT05789524 — The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B · Phase 2 · terminated
- NCT04073498 — The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05605678 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ApcinteX Ltd
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05605678.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing